Objectives: To evaluate the value of a classification of hydronephrosis on 18 F-flurodeoxyglucose (FDG)-PET/CT in predicting post-operative renal function and pathological outcomes among patients with upper urinary tract urothelial carcinoma. Methods: We retrospectively reviewed 71 patients treated with nephroureterectomy (NU) for upper urinary tract urothelial carcinoma after FDG-PET/CT between 2010 and 2016. Eight patients treated with ureteral stent or nephrostomy at the time of FDG-PET/CT were excluded. We classified hydronephrosis based on renal excretion of FDG as follows: Type 0, no hydronephrosis; Type 1, hydronephrosis with FDG excretion; and Type 2, hydronephrosis without FDG excretion. eGFR was recorded before pre-operataive FDG-PET/CT examination and after nephroureterectomy. Results: Thirty-three patients (52%) had hydronephrosis, classified as Type 1 in 19 patients (30%) and Type 2 in 14 (22%). Type 2 hydronephrosis was associated with ureteral cancer and severe hydronephrosis on CT. Median changes in eGFR before and after nephroureterectomy in patients classified as Type 0, 1 and 2 were −23.9, −18.8 and 2.0 ml/min/1.73 m 2 , respectively. On multivariate analysis, Type 2 hydronephrosis was a significant predictor of change in eGFR (P = 0.001).
Introduction
Upper urinary tract urothelial carcinomas (UTUCs), including renal pelvic cancer and ureteral cancer, accounts for about 5-10% of all urothelial carcinomas (1) . The standard therapy for non-metastatic UTUC is nephroureterectomy (NU). Additional lymphadenectomy (LND) and perioperative chemotherapy are considered in patients with a high risk of advanced cancer. Pathological tumor stage (pT), tumor grade and lymphovascular invasion are considered predictors of disease progression (2, 3) . Many of these factors are determined post-operatively. Pre-operative computed tomography (CT) urography offers high accuracy for diagnosing UTUC (4), but predicting pathological outcomes from CT is often difficult. Some authors have reported that pre-operative hydronephrosis is associated with advanced disease and poor oncologic outcomes based on conventional radiological findings (5-7). Furthermore, hydronephrosis offers a predictor of estimated glomerular filtration rate (eGFR) after NU (8) . On the other hand, recent reports have shown that 18 Ffluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT is useful for detecting primary and metastatic UTUC (9, 10) . In a recent report (11), FDG-PET/CT was also used to assess hydronephrosis, and renal excretion of FDG was significantly associated with the success of ureteral stenting in that study. This indicates that the absence of FDG excretion reflects more severe obstructive hydronephrosis. Until now, no studies have reported associations between clinicopathological outcomes and hydronephrosis on FDG-PET/CT in patients with UTUC. The aim of this study was to classify hydronephrosis based on FDG excretion and to evaluate the utility of this new classification in predicting post-operative renal function and pathological outcomes among patients with UTUC.
Patients and methods
All available clinicopathological data from 81 patients who underwent NU at our institution from September 2010 to December 2016 were retrospectively reviewed. Seventy-one patients underwent FDG-PET/CT at our institution for detecting metastasis before treatment. Patients treated with a ureteral stent or nephrostomy by the time of FDG-PET/CT were excluded. The remaining 63 patients were eligible for analysis. All the patients who underwent NAC, except one, were non-organ-confined disease on pretreatment imaging. Patient characteristics are shown in Table 1 . We excluded two patients with unilateral kidney before NU from analyses of renal function.
FDG-PET/CT was performed using a multislice PET/CT camera (Discovery PET/CT 600; GE Healthcare, Milwaukee, WI). All patients fasted for a minimum of 6 h with a blood glucose level of 80-120 mg/dl before intravenous administration of 18 F-FDG. About 500 mL of water was given to promote excretion of FDG. A whole-body image was obtained exactly 90 min after intravenous administration of 222-370 MBq (6-10 mCi) of 18 F-FDG. PET emission images were corrected for measured attention and reconstructed using an ordered-subset expectation maximization iterative algorithm as per the instructions from the manufacturer. Integrated PET/CT images were reviewed on an Advantage Workstation (GE Healthcare). The display field of view was 60 × 60 cm, comprising a 192 × 192 matrix. Voxel size was 3.125 × 3.125 × 3.27 mm 3 . Two types were investigated for the visual evaluation of hydronephrosis based on renal excretion of FDG. FDG renal excretion was visually assessed as either present or absent (11). We classified hydronephrosis on FDG-PET/CT as follows: Type 0, no hydronephrosis; Type 1, hydronephrosis with FDG excretion; and Type 2, hydronephrosis without FDG excretion (Fig. 1) . Two experienced nuclear medicine physicians independently interpreted the FDG-PET/CT images. The concordance rate for interpretation of the FDG-PET/CT images by two nuclear medicine physicians was 96.8% (61/63). In two cases of discordant findings, the final decision was made by consensus. Hydronephrosis on CT was graded as grade 0-no caliceal or pelvic dilatation, grade 1-pelvic dilatation only, grade 2-mild caliceal dilatation, grade 3-severe caliceal dilatation and grade 4-caliceal dilatation accompanied by renal parenchymal atrophy (12) . Final pathological diagnosis was performed with the specimen obtained from NU. LND in conjunction with NU was performed in 35 patients. Tumor classification was assessed according to the TNM classification of the American Joint Committee on Cancer-Union International contre le Cancer.
Pre-and post-operative serum creatinine levels and eGFR were recorded before FDG-PET/CT examination and within 1 month after NU, respectively. We then calculated eGFR using the Modification of Diet in Renal Disease equation for Japanese: eGFR (ml/min/1.73
The Mann-Whitney U-test, Kruskal-Wallis test, chi-square test were used to assess associations between clinicopathological features and classification of hydronephrosis on FDG-PET/CT. Binary logistic regression analysis was applied to assess the relationship between pre-operative variables and muscle-invasive UTUC in multivariate analysis. Linear regression analysis was applied to assess the relationship between pre-operative variables and change in eGFR before and after NU. A value of P < 0.05 was considered statistically significant. SPSS version 21 software (IBM Corp, Armonk, NY) was used for all statistical analyses.
Results
Overall, 63 patients (54 men, 9 women) were included in this study. Clinical characteristics of the study population are shown in Table 1 . Hydronephrosis was identified in 33 patients (52%), classified as Type 1 in 19 patients (30%) and Type 2 in 14 patients (22%). Type 2 hydronephrosis was associated with ureteral cancer and severe hydronephrosis on CT. Patients with Type 2 hydronephrosis displayed significantly lower pre-operative eGFR than patients without hydronephrosis (42.8 vs 63.1 ml/min/1.73 m 2 ).
Patients with Type 2 hydronephrosis showed almost no change in eGFR before and after NU (2.0 ml/min/1.73 m 2 ). On multivariate linear regression analysis, pre-operative eGFR and Type 2 hydronephrosis were significantly predictors of change in eGFR (Table 2) .
Pathological characteristics of 63 patients are shown in Table 3 . The number of patients with ≥pT2, pathological grade 3, lymphovascular invasion (LVI 1) was 31 (49%), 28 (46%) and 25 (40%), respectively. Type of hydronephrosis was significantly associated with pathological grade 3, LVI 1, ≥pT2 (P < 0.05). Type 2 hydronephrosis showed a high positive predictive value (86%) for muscleinvasive UTUC (Table 4 ). In the cases of ureteral cancer, no patients without hydronephrosis showed muscle-invasive cancer. On multivariate analysis, Type 2 hydronephrosis was a significant predictor of muscle-invasive UTUC (Table 4) .
Discussion
NU represents the current standard therapy for UTUC, and addition of LND or perioperative chemotherapy is likely to be beneficial for muscle-invasive or high-risk disease (14) (15) (16) .
A recent review suggested promising response rates for neoadjuvant chemotherapy (NAC) and survival benefit for adjuvant chemotherapy (AC), although most studies examining either cisplatin-based NAC or AC have been retrospective in design (14) . Theoretical advantages of NAC include the eradication of micrometastatic disease, pathological downstaging and eligibility of cisplatin before NU. However, a delay in NU and unnecessary administration of chemotherapy are disadvantageous to patients who do not respond to NAC. In contrast to NAC, selection of patients to receive AC appears adequate when based on pathological outcomes. Renal function is very important in patients receiving perioperative chemotherapy, as cisplatin eligibility is decided by renal function. Some patients who underwent NU experienced a great decrease in eGFR, but others did not (17, 18) . The presence of hydronephrosis was an independent predictor of the difference between pre-and post-operative eGFR (8) . Cho et al. reported that four PET patterns based on FDG renal parenchymal uptake and excretion correlated linearly with severity of hydronephrosis and serum creatinine levels. In particular, the absence of FDG excretion was significantly associated with stent failure, but CT hydronephrosis grade was not. The absence of FDG excretion means renal dysfunction and severe obstructive hydronephrosis (11). We therefore focused on FDG excretion and classified the hydronephrosis on FDG-PET/CT as follows: Type 1, presence of FDG excretion; and Type 2, absence of FDG excretion. We identified that pre-operative renal function was low and renal function did not change with NU in patients with Type 2 hydronephrosis. From that result, we think that no renal function of the disease-side unit may remain in patients with Type 2 hydronephrosis. This finding may help in deciding the adequacy of NAC or AC. Previous studies have reported that no or lower grade hydronephrosis and low contralateral kidney volume were associated with the risk of renal dysfunction and ineligibility for adjuvant cisplatin-based chemotherapy resulting from NU (19, 20) .
The benefit of LND has been demonstrated in some studies. A significant difference in cancer-specific survival (CSS) was identified between pN0 and pNx patients with muscle-invasive UTUC (5-year CSS: 73% vs 48%) (21). Abe et al. detected a significant difference in recurrence-free survival between pN0 and pNx in (13) 1 (5) patients with muscle-invasive UTUC patients but not in patients with pT1 disease (22) . Furthermore, LND was significantly associated with overall survival (23) . This is associated with the incidence of lymph node metastases according to pathological stage. A UTUC of pT1 or lower rarely metastasizes to regional nodes. On the other hand, the incidence of nodal involvement was 8% in pT2, 27% in pT3 and 79% in pT4 (16) . Thus, patients who benefit from LND have been assumed to be patients with muscle-invasive UTUC. However, pre-operative primary tumor staging of UTUC using imaging is often difficult. CT cannot adequately distinguish between pTa, pT1 and pT2 UTUC (24) . In the relationship between clinical stage as diagnosed from preoperative CT and pathological stage, 43% of patients with cT1 or lower were upstaged to pT2 or higher, and 29% of patients with cT2 were downstaged (16) . Ipsilateral hydronephrosis was associated with muscle-invasive UTUC (5, 6) . These findings imply that muscle-invasive UTUC causes more severe luminal obstruction as well as intramural invasion or extrinsic compression. We could further divide hydronephrosis into Types 1 and 2 based on FDG excretion associated with severity of obstructive hydronephrosis. As a result, Type 2 hydronephrosis showed a higher PPV for muscle-invasive UTUC than the presence of hydronephrosis on CT in our study. Furthermore, no ureteral cancer patients with Type 0 had muscle-invasive disease. LND may thus be considered indicated in ureteral cancer patients with Type 2 hydronephrosis and not in patients without hydronephrosis.
We acknowledge several limitations in this study. Our study represents a retrospective analysis of small sample size from a single institution. Further studies with a larger number of patients are required. However, we believe that our classification can identify patients for whom LND or neoadjuvant cisplatin-based chemotherapy may be beneficial. This is the first study to demonstrate that a classification of hydronephrosis from FDG-PET/CT predicted postoperative renal function and pathological outcome in patients with UTUC. 
Conclusion
We were able to clearly and easily classify hydronephrosis based on renal excretion of FDG. Hydronephrosis without renal excretion of FDG predicted muscle-invasive UTUC and no change in renal function resulting from NU. This classification may be useful for deciding eligibility for neoadjuvant cisplatin-based chemotherapy or LND. 
